HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified
On August 10, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of HCW Biologics Inc. (the "Company"), in consultation with management and the Company’s independent registered
HCW Biologics made a big mistake in their math when they reported how much money they earned—they said they made more than they actually did. When a company finds this kind of error, it means people need to be extra careful and watch closely to see if the company fixes their counting system.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.